Among these, positron emission tomography/computed tomography (PET/CT) with prostate-specific membrane antigen (PSMA) ligands has gained prominence for its high sensitivity and specificity in identifying tumor burden, especially in advanced stages. The gene discussed is FOLH1; the disease is neoplasm.